15.11.2016 • NewsElaine BurridgeAcidsmethionine

Evonik Bids for Metabolic Explorer’s Methionine Assets

(c) Evonik
(c) Evonik

German specialty chemicals company Evonik has submitted a binding offer to acquire the methionine technology and other assets of French biochemistry company Metabolic Explorer. Financial details were not disclosed. The offer, submitted on Oct. 27, also includes patents, essential bacteria strains and the inoLa brand, an additive rich in l-methionine with secondary amino acids and organic acids for animal nutrition that was launched in April. These will be transferred to Evonik at the time the transaction completes.

The proposed deal also includes a back license agreement allowing Metabolic Explorer to continue using certain patents for activities other than those relating to methionine. The two companies will also explore a research and development cooperation for the manufacture of biotechnologically produced amino acids. A “timely conclusion” is planned for the transaction, which is subject to final approval from both company’s boards. Metabolic Explorer said its shareholders approved the sale of its methionine technology at a general meeting on Sept. 29 and discussions were initiated with several potential partners in the amino acids business.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.